The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Recent advancements in the understanding of Richter’s transformation
In this video, Elisa Ten Hacken, PhD, Weill Cornell Medicine, New York, NY, briefly discusses recent advancements in understanding Richter’s transformation (RT), highlighting the role of next-generation sequencing (NGS) studies in identifying genetic drivers specific to this condition. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We have learned quite a bit in Richter’s transformation in recent years, thanks to the next-generation sequencing studies of very large patient cohorts. And what we incompletely understand is the function of selected genetic drivers that appear to be specific to Richter’s transformations compared to CLL. And we are now equipped with molecular models and cell line and mouse models that can help us address these questions...
We have learned quite a bit in Richter’s transformation in recent years, thanks to the next-generation sequencing studies of very large patient cohorts. And what we incompletely understand is the function of selected genetic drivers that appear to be specific to Richter’s transformations compared to CLL. And we are now equipped with molecular models and cell line and mouse models that can help us address these questions. And actually, my lab is very much focused on functional genomic analysis, leveraging my own mouse models of Richter’s transformation. We have very compelling new data that we hope to present soon on the relevance of specific drivers in changing both tumor intrinsic and extrinsic properties that may favor disease evolution.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
